html5-img
1 / 21

Contemporary Treatment of Metastatic Non-Small Cell Lung Cancer

Contemporary Treatment of Metastatic Non-Small Cell Lung Cancer. Jeffrey A. Bubis , DO, FACOI, FACP Cancer Specialists of North Florida Baptist South and Fleming Island. Lung Cancer Stats. Leading cause of cancer death in U.S. Predicted 2014 demographics 224,210 new cases

tara
Télécharger la présentation

Contemporary Treatment of Metastatic Non-Small Cell Lung Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Contemporary Treatment of Metastatic Non-Small Cell Lung Cancer Jeffrey A. Bubis, DO, FACOI, FACP Cancer Specialists of North Florida Baptist South and Fleming Island

  2. Lung Cancer Stats • Leading cause of cancer death in U.S. • Predicted 2014 demographics • 224,210 new cases • 116,000 men and 108,210 women • 159,260 deaths • 86,930 men and 72,330 women • 5 year OS is 16.6% http://seer.cancer.gov/statfacts/html/lungb.html)

  3. Classification • WHO • SCLC • NSCLC • NSCLC is 85% of all lung cancer cases • Squamous cell Carcinoma • Non-Squamous Cell Carcinoma • Adenocarcinoma (Most common) • Large cell Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J ThoracOncol 2011;6:244-285.

  4. Pathologic Evaluation • Biopsies should be with a core needle or with multiple FNA specimens • All specimens should be tested for: • EGFR • ALK • If limited tissue is available, this is more important than IHC • TTF-1 negative/p63 positive = SCC • TTF-1 positive/p63 negative = NSNSCLC

  5. Prognostic Factors • Early stage disease • Good performance status (ECOG 0, 1, 2) • Weight loss <5% • Female gender Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J ClinOncol 1986;4:702-709.

  6. Treatment Options • Stage I-II • Surgery +/- chemotherapy • Radiotherapy (non surgical candidates) • Stage III • Surgery + chemotherapy • Chemotherapy+radiation • Chemotherapy • Stage IV • Systemic therapy +/- radiation NCCN guidelines http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.

  7. Treatment Options For Metastatic Disease • Cytotoxic chemotherapy • Pros • Reduces symptoms • Improves quality of life • Improves overall survival • Cons • Nonspecific

  8. Treatment Options For Metastatic Disease • Targeted Therapy • Pros • Reduces symptoms • Improves quality of life • Improves progression free survival • May have reduced toxicity relative to cytotoxic therapy • Cons • Nonspecific

  9. Historic Perspective on Front Line Therapy of NSNSCLC • Until the mid-2000’s • Platinum and non-platinum doublet therapies • Carboplatin + taxane • Carboplatin + gemcitabine • 2006 • Bevacizumab FDA approved • 2009 • Pemetrexed FDA approved

  10. EGFR Activating Mutations • Seen in 15% of NSCLC in the U.S. • More frequent in non-smokers • Up to 62% of Asian (especially females) • Favorable prognosis • Predicts sensitivity to EGFR tyrosine kinase inhibitors • Erlotinib and afatinib

  11. EGFR Positive • EGFR TKIs • Front line • Improve PFS compared to standard platinum-based therapy • Continue until progression or intolerance • Second line

  12. EGFR TKI Data • Meta-analysis of 13 phase III trials with 2620 patients demonstrated • PFS improved • No change in OS Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013; 105:595.

  13. EGFR TKI Data • OPTIMAL • 154 patients • Erlotinibvs Carboplatin/Gemcitabine • PFS 13.1 vs 4.6 months • ORR 83 vs 36% Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735.

  14. EGFR TKI Data • EURTAC • 174 patients • Erlotinib vs. platinum doublet • PFS 9.7 vs 5.2 months • OS 19.3 vs 19.5 months • Crossover design Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239.

  15. EGFR TKI Toxicities • Rash • Usually mild • Usually responsive to topical therapies or doxycycline • Diarrhea • Rarely severe • Usually responsive to loperamide • Interstitial pneumonitis • Hepatic toxicity

  16. ALK Translocation • Present in 4% of NSCLC in the U.S. • More frequent in nonsmokers • More frequent in younger patients • Predicts for sensitivity to ALK tyrosine kinase inhibitors • Crizotinib

  17. ALK Trial Data • 347 patients with ALK+ NSCLC that was previously treated with a platinum doublet randomly assigned to crizotinib or single agent chemotherapy. Crossover was allowed. • PFS was better with crizotinib (7.7 vs 3.0 months) • RR was better with crizotinib (65 vs 20%) • OS unchanged (20.3 vs. 22.8 months) Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385.

  18. ALK TKI Toxicities • Visual disturbances (dark to light transitions) • N/V/D/constipation • Transaminitis • Bradycardia • QTc prolongation • Serum testosterone depression • Pneumonitis

  19. Other Targets Under Investigation

  20. Immunotherapy • Anti-CTLA-4 • Anti-PD1/PDL1 • Vaccines

  21. Thank you.

More Related